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Abstract
Background: Intrauterine growth retardation (IUGR) is a major risk factor for perinatal mortality and morbidity. Thus,
there is a compelling need to introduce sensitive measures to detect IUGR fetuses. Routine third trimester
ultrasonography is increasingly used to detect IUGR. However, we lack evidence for its clinical effectiveness and
cost-effectiveness and information on ethical considerations of additional third trimester ultrasonography. This
nationwide stepped wedge cluster-randomized trial examines the (cost-)effectiveness of routine third trimester
ultrasonography in reducing severe adverse perinatal outcome through subsequent protocolized management.
Methods: For this trial, 15,000 women with a singleton pregnancy receiving care in 60 participating primary care
midwifery practices will be included at 22 weeks of gestation. In the intervention (n= 7,500) and control group (n= 7,500)
fetal growth will be monitored by serial fundal height assessments. All practices will start offering the control condition
(ultrasonography based on medical indication). Every three months, 20 practices will be randomized to the intervention
condition, i.e. apart from ultrasonography if indicated, two routine ultrasound examinations will be performed (at 28–30
weeks and 34–36 weeks). If IUGR is suspected, both groups will receive subsequent clinical management as described in
the IRIS study protocol that will be developed before the start of the trial.
The primary dichotomous clinical composite outcome is ‘severe adverse perinatal outcome’ up to 7 days after birth,
including: perinatal death; Apgar score <4 at 5 minutes after birth; impaired consciousness; need for assisted ventilation for
more than 24 h; asphyxia; septicemia; meningitis; bronchopulmonary dysplasia; intraventricular hemorrhage; cystic
periventricular leukomalacia; neonatal seizures or necrotizing enterocolitis. For the economic evaluation, costs will be
measured from a societal perspective. Quality of life will be measured using the EQ-5D-5 L to enable calculation of QALYs.
Cost-effectiveness and cost-utility analyses will be performed. In a qualitative sub-study (using diary notes from 32 women
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for 9 months, at least 10 individual interviews and 2 focus group studies) we will explore ethical considerations of
additional ultrasonography and how to deal with them.
Discussion: The results of this trial will assist healthcare providers and policymakers in making an evidence-based decision
about whether or not introducing routine third trimester ultrasonography.
Trial registration: NTR4367, 21 March 2014.
Keywords: Intrauterine growth retardation, Perinatal outcome, Midwifery, Third trimester ultrasonography
Background
Monitoring fetal growth and well-being is a major ob-
jective of prenatal care [1]. Intrauterine growth retard-
ation has often been defined as failing to achieve a
specific fetal biometric or estimated fetal weight thresh-
old by a specific gestational age [2]. IUGR is a risk factor
for adverse outcomes, including perinatal death, neo-
natal encephalopathy, neurodevelopmental impairments
in childhood, and disease in adult life [3–6]. To be able
to provide timely clinical management for these fetuses,
sensitive screening procedures for the detection of IUGR
are needed. In many Western countries, including the
Netherlands, primary midwifery and/or obstetric care
mainly consist of serial fundal height assessments to
monitor fetal growth patterns. Yet, this approach is not
very effective as it only detects about one fifth or fewer
neonates being small-for-gestational-age (birth weight
<10th percentile by gestational age) [7–9], which is
troublesome as being small-for-gestational-age (SGA) is
a common finding among perinatal deaths [10, 11].
An alternative approach to detect IUGR fetuses comprises
routine third trimester ultrasonography. A recent prospect-
ive cohort study (n = 3977) demonstrated that routine third
trimester ultrasonography using estimated fetal weight or
abdominal circumference approximately almost tripled the
detection rate of SGA neonates (sensitivity = 57 %) [12].
Routine third trimester ultrasound screening may have other
benefits, including the detection of structural fetal abnor-
malities, e.g. craniospinal abnormalities and urinary tract ab-
normalities, which become manifest late in pregnancy [13].
However, a meta-analysis of 13 randomized trials among
low-risk pregnancies (n = 34,980) did not reveal beneficial
effects of third trimester ultrasound screening on primary
outcomes of perinatal mortality, preterm birth less than
37 weeks, Caesarean section rates, and induction of labor
rates [14]. Two major shortcomings have been identified in
these previous trials [14, 15]. First, previous trials had meth-
odological shortcomings, e.g., most trials were underpow-
ered to detect clinically significant differences in severe
perinatal outcomes, heterogeneity in number and timing of
ultrasound scans, and contamination, i.e., ultrasound scans
were often also conducted in the control group [14, 15].
Secondly, in many trials only the ultrasound screening pro-
cedure was described but not the use of subsequent
management/intervention procedures when IUGR is sus-
pected. If not coupled with an effective intervention, ultra-
sound screening alone cannot be clinically effective [12].
Moreover, ultrasound technology used in most previous tri-
als is now outdated [14, 15]. Reviews on the effects of rou-
tine third trimester ultrasound screening on pregnancy and
perinatal outcome concluded that a large-scale trial with ad-
equate power is needed to address severe adverse perinatal
outcomes and to examine long-term neurodevelopmental
outcome in the offspring [14, 16].
Introducing a screening program can have negative con-
sequences, such as unnecessary medical care [17]. Defining
IUGR based on a certain cut-off, e.g., the lowest 10th per-
centile of estimated fetal weight, will probably not only lead
to the detection of growth restricted fetuses but also to the
classification of a group of ‘at risk fetuses’ who are consti-
tutionally small and healthy. This may lead to unnecessary
interventions, such as elective induction of delivery.
Moreover, additional third trimester ultrasonography may
affect maternal emotions, either positively in that negative
screening results may be reassuring, or negatively in that it
may increase maternal emotional distress, i.e., anxiety or de-
pressive symptoms. Women may experience higher levels of
emotional distress, due to an (incorrect) indication of IUGR
and be exposed to additional monitoring and obstetric inter-
ventions [18, 19]. Experiences of maternal emotional distress
due to positive, unexpected or unclear findings based on
fetal ultrasound screening may continue into the postpar-
tum period, even when abnormal screening results have not
been confirmed by subsequent examinations [20–22].
In the case of positive screening results routine third
trimester ultrasonography may particularly be related to
the experience of moral dilemmas by pregnant women
and professionals performing ultrasonography. For ex-
ample, parents may find this burdensome due to in-
creased responsibility that comes with the fact that they
have to choose for further examinations of the fetus (or
not). Professionals may find it difficult how to decide
how much and which information they should provide
to women/parents and when to advice referral for fur-
ther clinical management [20–23].
Despite the lack of evidence for its clinical effective-
ness [14, 15], routine third trimester ultrasound screen-
ing is increasingly used in midwifery care in the
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Netherlands, which results in a considerable rise in
health care costs. Few former studies evaluated the cost-
effectiveness of ultrasound scans [24, 25]. Although costs
of the ultrasound examination itself have previously
been investigated, we know little about resulting costs
(e.g., costs associated with subsequent counselling,
follow-up examinations, and subsequent interventions).
So far, only one previous trial, The Helsinki ultrasound
trial, addressed this matter showing that one-stage
second-trimester ultrasound screening is cost-effective
in reducing perinatal mortality as compared to care as
usual when taking all significant costs and effects into
account [25]. Moreover, the cost-effectiveness of routine
third-trimester ultrasound screening combined with ser-
ial fundal height measurements and clinically indicated
ultrasonography as compared to care as usual (CAU),
i.e. serial fundal height measurements and clinically indi-
cated ultrasonography alone, has not been studied
earlier.
In the Netherlands, at the moment no multi-
disciplinary consensus exists concerning the screening
for and clinical management of suspected IUGR. To be
more specific, the current monodisciplinary Dutch
guidelines of the Royal Organization of Midwifes in the
Netherlands (KNOV) and of the Dutch Association of
Obstetrics and Gynecology (NVOG) for IUGR detection
or management have a different focus and do not fully
align [26, 27]. This may lead to inconsistent approaches
in the clinical management of suspected IUGR. There-
fore, another key element of our study is the develop-
ment of a consensus-based multidisciplinary protocol for
the detection and subsequent management of suspected
IUGR using a Delphi study.
Research aims
The main aim of the (IUGR risk selection study) IRIS
study is to assess the effectiveness and cost-effectiveness
of routine third trimester ultrasound screening at 28–30
weeks and at 34–36 weeks of gestation in comparison
with CAU in reducing severe adverse perinatal outcome
among low-risk pregnant women through subsequent
protocolized management. The research aims of the IRIS
study are:
1. To evaluate whether routine third trimester
ultrasound screening combined with subsequent
protocolized management reduces severe adverse
perinatal outcome as compared to CAU and
subsequent protocolized management.
2. To evaluate whether routine third trimester
ultrasound screening combined with subsequent
protocolized management is cost-effective as com-
pared to CAU and subsequent protocolized
management.
3. To develop a multidisciplinary consensus‐based
protocol for the detection and management of IUGR
and to study professionals’ adherence to the
protocol.
4. To examine whether routine third trimester
ultrasound screening combined with subsequent
protocolized management affects maternal prenatal
and postnatal psychological functioning and infant
neurodevelopment at age 6 and 24 months as
compared to CAU and subsequent protocolized
management.
5. To examine ethical dilemmas concerning positive,
unclear, and unexpected findings and incorrect
indication ofIUGR and to explore what professionals
and women recommend regarding the handling of
these ethical dilemmas.
Methods/design
Study design
The IRIS study is a nationwide stepped wedge cluster-
randomized trial among 15,000 low-risk pregnant
women receiving care at 60 midwifery practices in the
Netherlands. The intervention entails routine third tri-
mester ultrasound screening combined with serial fundal
height measurements and clinically indicated ultrason-
ography, while the control condition entails CAU (serial
fundal height measurements and clinically indicated
ultrasonography only). In 1500 pregnant women derived
from the entire study population a survey will be con-
ducted to assess societal costs, maternal psychological
functioning, maternal quality of life, and infant neurode-
velopment. The exact design of the survey will be de-
scribed in more detail later on.
Two sub-studies will be conducted as part of the IRIS
study. In sub-study A, a Delphi study will be conducted
to develop a multidisciplinary consensus-based protocol
for the detection and subsequent management of IUGR
in the Netherlands. Sub-study B will address ethical con-
siderations of additional/routine third trimester ultra-
sound screening. These sub-studies will be described in
more detail later on.
Participants/eligibility criteria of participating midwifery
practices
Practices will be eligible if all midwives are willing to fol-
low the postgraduate registration training in the guide-
line ‘detection of IUGR’ of the KNOV [26]. Inclusion
criteria for ultrasonographers that perform ultrasounds
for women in the IRIS study are: 1) they have success-
fully followed the e-learning training for fetal biometry
of the national medical e-learning education programs
for medical students and professionals in the
Netherlands (www.medischonderwijs.nl); 2) they possess
a certificate for ultrasound anomaly screening (‘SEO’
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certificate’) or will be judged as adequate performers of
ultrasonography (based on 4 cases) by an IRIS study so-
nographer; 3) they use ultrasound equipment according
to the standards of the NVOG [27]. Some midwifery
practices perform ultrasound in their own practice;
others refer to an ultrasound center.
Inclusion criteria for pregnant women are 1) receiving
care in the participating midwifery practice at 22 weeks
of gestation, having a singleton pregnancy and having no
major obstetric or medical risk factors; and 2) having a
reliable estimated date of delivery based on a dating
ultrasound scan in line with NVOG guidelines or based
on the first day of the last menstrual period [27].
Recruitment and randomization
Figure 1 shows the flow chart of the study design. Midwif-
ery practices will be informed about the IRIS study and
invited to participate in the study via our nationwide Del-
phi study (sub‐study A). Other methods to invite midwifery
practices for participation will include attending meetings
of regional maternity care networks and the postgraduate
training about the KNOV guideline [26], articles in national
professional journals, and social media. A researcher will
visit interested midwifery practices to provide information
about the IRIS study, check whether the practice fulfils the
inclusion criteria, and ask the midwives to sign a contract
to demonstrate their commitment to the study protocol.
During the first consultation after the 20-weeks preg-
nancy ultrasound screening has been offered, eligible
pregnant women will be given a trial information leaflet
by their midwife. The midwife will obtain consent.
Midwifery practices will form the unit of randomization.
Randomization per practice rather than per midwife or
woman minimizes contamination and maximizes contrast
Fig. 1 Flow chart study design
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between the intervention and control group. As shown in
Fig. 2, all midwifery practices (n = 60) will start in the con-
trol group. At 3 months intervals, a third of the midwifery
practices will change status from the control to the inter-
vention condition. To balance the number of women in
the two conditions, practices will be stratified before
randomization in large and small practices, with the aver-
age practice size as cut‐off (250 women per year). A strati-
fied computer‐generated random sequence will determine
the order in which practices change from control to inter-
vention status. Randomization will be conducted by an in-
dependent statistician at 3 and 6 months after the start of
baseline data collection and the recruitment of the first
participating women.
Care in the intervention and control group
Both the intervention group and the control group
will receive the following standard elements of mid-
wifery care: 1) serial fundal height measurements and
clinically indicated ultrasonography in line with the
KNOV guideline for the detection of IUGR [26]; 2)
information about life-style factors that may influence
fetal development, e.g., smoking and alcohol use; and
3) advice to report a reduction in fetal movements.
When IUGR is suspected, both groups will receive
subsequent management based on the consensus-
based protocol that will be developed in sub-study A.
Intervention
In the intervention group two routine third trimester bi-
ometry ultrasounds will be performed, the first at 28–30
weeks of gestation and the second at 34–36 weeks of
gestation. Performing two ultrasound examinations en-
ables detection of early and late fetal growth restriction
and allows monitoring of fetal growth patterns, which
may reveal decreased fetal abdominal growth velocity.
Measures
Baseline characteristics of pregnant women and midwifery
practices
To assess comparability of study groups and predictors of
outcome, data on baseline characteristics of participating
midwifery practices and participating pregnant women will
be collected. Baseline characteristics of midwifery practices
will include number of midwives working in the practice,
number of clients per year, proportion of nulliparous and
multiparous women, and rate of referral to secondary/ter-
tiary care. Maternal baseline characteristics will include eth-
nic background, maternal age, educational level, height and
weight, smoking, alcohol use, drug use, and work status
during pregnancy.
Primary outcome – severe adverse perinatal outcome
The primary dichotomous clinical outcome of the main
study will be a composite measure of severe adverse perinatal
outcomes up to 7 days after birth defined as one or more of
the following:
1) Antepartum, intrapartum or perinatal death occurring
from 28 weeks of gestation onward
2) Apgar score <4 at 5 min after birth;
3) Coma, stupor or decreased response to pain up to
7 days after birth;
4) Asphyxia, defined as cord blood arterial base excess
of less than minus 12;
5) Neonatal seizures defined as clonic movements
which cannot be stopped by holding the limb,
occurring on two or more occasions before 72 h of
age;
6) Assisted ventilation for more than 24 h via
endotracheal tube initiated within 72 h after birth;
7) Septicemia, ascertained by a positive blood culture;
8) Meningitis, ascertained by positive cerebrospinal
fluid culture;
9) Bronchopulmonary dysplasia (BPD), defined as need
for oxygen at a postnatal gestational age from 36
completed weeks as well as an X‐ray compatible
with BPD;
10)Intraventricular hemorrhage, defined as grade 3 or 4
and diagnosed by cranial ultrasound or at autopsy
11)Cystic periventricular leukomalacia (PVL), diagnosed
by cranial ultrasound or at autopsy showing
periventricular cystic changes in the white matter
excluding subependymal and choroid plexus cysts;
Fig. 2 The stepped wedge design of the IRIS study. Pregnant women will be enrolled during months 1–12 at 20–22 weeks of gestation. All
midwifery practices (n = 60) will start with the control condition providing care as usual. At intervals of 3 months, a third of all practices will
change status from the control to the intervention condition, which means providing routine third trimester ultrasound screening at 28–30
weeks and 34–36 weeks of gestation. Postnatal follow-up will be conducted in months 18–42
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12)Necrotizing enterocolitis, defined as either
perforation of intestine, pneumatosis intestinalis or
air in the portal vein, diagnosed by X‐ray or surgery,
or at autopsy.
Primary outcome - costs
Healthcare costs will include costs related to pregnancy-
related healthcare use, including community midwife
consultations, referrals to specialist care, ultrasound ex-
aminations, laboratory tests, CTG monitoring, hospital
admission, interventions during labor, and admission to
neonatal unit. Healthcare costs will be calculated using
standard costs published in the Dutch costing guidelines
[28]. Medication use will be calculated using prices of
the Royal Dutch Society for Pharmacy.
Absenteeism and presenteeism at work (indirect costs)
as reported by (pregnant) women will be assessed by the
iMTA Productivity Cost Questionnaire (iPCQ) [29].
The friction cost approach will be used to estimate in-
direct costs using Dutch age and sex specific lost prod-
uctivity costs [30, 31].
Secondary outcome measures- composite outcome
Two other dichotomous composite outcomes are de-
fined as secondary outcomes. The first is spontaneous
vaginal birth without intervention, i.e., a birth without
any of the following interventions: 1) induction of labor
other than amniotomy, 2) vacuum/forceps assisted birth,
3) Caesarean section; 4) augmentation of labor; and 5)
pharmacological pain relief.
Secondly, another secondary dichotomous composite
outcome is maternal perinatal morbidity/mortality, de-
fined as the presence of one or more of the following: 1)
maternal death within 42 days after giving birth, 2)
hypertension, 3) pre‐eclampsia, 4) postpartum
hemorrhage larger than 1000 mL, and 5) third or fourth
degree perineal trauma.
Secondary outcomes – single outcomes
Single outcomes include the different elements of the
composite primary outcome and the secondary compos-
ite outcome. Other secondary single outcomes will be
neonatal mortality and severe morbidity between the 7th
and 28th day after birth, congenital abnormalities, life
threatening congenital conditions among neonates, non‐
cephalic presentations (when labor started) in primary
care, and place of birth. Mean birth weight, low birth
weight, macrosomia, mean gestational age, and prema-
turity will also be single secondary outcomes.
Other secondary single outcomes, that will be reported
by women participating in the survey (n = 1500), will in-
clude 1) maternal prenatal and postnatal quality of life
(EQ‐5D‐5 L and one item of the short form health survey
(SF-36) [32–34]); 2) maternal experience of continuity of
healthcare and satisfaction with healthcare during preg-
nancy and delivery (Nijmegen Continuity Questionnaire
(NCQ) and Pregnancy and Childbirth Questionnaire
(PCQ)) [35, 36]; 3) maternal pre- and postnatal anxiety
and pregnancy-specific anxiety (State and Trait Anxiety
Inventory (STAI) [37], and the Pregnancy Anxiety
Questionnaire-Revised (PRAQ-R)) [38]; 4) and pre- and
postnatal depressive symptoms (Edinburgh (Postpartum)
Depression Scale) [39, 40]; and 5) prenatal and postnatal
maternal bonding, i.e., the emotional tie between the
mother and the (unborn) child (Maternal Antenatal At-
tachment Scale (MAAS) and Maternal Postnatal Attach-
ment Scale (MPAS)) [41, 42]. Moreover, other secondary
single outcomes will be infant developmental milestones at
age 6 months assessed with the Ages and Stages Question-
naire (ASQ) and toddlers’ behavioral problems and devel-
opmental milestones at 24 months measured via the Child
Behavior Checklist (CBCL) and ASQ, respectively [43–45].
In a purposively selected subsample of pregnant women
(n ~ 15) participating in the intervention group, semi-
structured interviews will be conducted during late preg-
nancy to explore and better understand the role of third
trimester ultrasound screening in the experience of mater-
nal pregnancy-specific anxiety and maternal bonding.
Process measures
To evaluate the uptake of the intervention and the adher-
ence to the consensus-based IRIS study protocol for the
detection and management of IUGR, a number of process
measures will be assessed, including the rate of women
declining participation, the proportion of protocol viola-
tions, proportion of disagreements in primary outcomes
based on reassessments by research assistants/nurses, and
opinions of midwives on (in)effective elements of the
intervention. Data on protocol adherence will be collected
via standardized forms filled out by a researcher attending
several multidisciplinary case evaluations or audits in case
of perinatal deaths or severe adverse perinatal outcome.
Protocol adherence will also be assessed via standardized
case report forms filled out by research assistants/nurses
using hospital records of a subsample of neonates and
women (n ~ 2000) displaying perinatal/postpartum mor-
bidity/mortality (for more detail see subsection data col-
lection). Using a short questionnaire, we will evaluate
community midwives’ experience of cooperation with
healthcare professionals in secondary care in terms of the
IRIS study protocol after the completion of the inclusion
period.
Data collection
Baseline questionnaire midwifery practice and women
Via a short questionnaire midwives will report characteris-
tics of their midwifery practices based on the most recent
Dutch national midwifery care report [46]. After enrolment,
Henrichs et al. BMC Pregnancy and Childbirth  (2016) 16:310 Page 6 of 11
using short questionnaires, participating women and mid-
wives will report maternal baseline characteristics, includ-
ing data on demographics and anthropometrics.
Existing medical databases/registries
For the main study (n = 15,000), data will be extracted
from the following existing databases: 1) the database of
the Perinatal Registry of the Netherlands (Perined); 2)
ultrasound centers’ databases; 3) hospital medical records
of mothers and neonates if applicable. These databases
will be used to collect data on (primary) clinical outcomes,
obstetric variables, ultrasound scans, and care processes.
Survey
Two subsamples will be derived from the complete study
population (see Fig. 1) for a detailed assessment of societal
costs, maternal quality of life, maternal experience of health-
care during the perinatal period, maternal psychological
functioning (maternal depressive symptoms, anxiety, and
bonding), and infant neurodevelopment. These two subsam-
ples comprise the following: (a) a random sample of 900
women (450 intervention and 450 CAU) who will be asked
to complete online questionnaires around 22 weeks of gesta-
tion, at 32 weeks of gestation, and at 6 weeks, 6 months,
and 24 months after estimated date of delivery (n = 15 per
midwifery practice); and (b) a non-random sample compris-
ing 600 women in whom IUGR is suspected by fetal ultra-
sonography (300 intervention and 300 CAU) and who will
be asked to complete online questionnaires (n= 10 per mid-
wifery practice) after the suspicion of IUGR during late
pregnancy, at 6 weeks and 6 and 24 months postpartum. At
the age of 24 months, we will ask mothers participating in
the survey and mothers of toddlers having (a) severe adverse
perinatal outcome(s) (see above for the definition of our pri-
mary clinical outcome) to report toddlers’ developmental
milestones and behavioral problems.
For the survey, we will recruit 1500 women prenatally.
Based on an expected non-response and drop-out rate
of 33 %, we expect to collect complete follow-up data in
1000 women in the random (n = 600) and non-random
sample (n = 400).
Women who will participate in the survey will give
additional consent to participate in the survey and will
receive an e-mail with a link to an online questionnaire
at each measurement time point. Non-responding preg-
nant women will receive reminders via e-mail. To en-
hance participation of non-Dutch speaking women, the
questionnaires will be translated into English. These
questionnaire data will be collected through telephone
interviews conducted by a researcher.
Hospital medical records
Using standardized case report forms research assis-
tants/nurses will collect detailed information from
approximately 2000 hospital medical records on health-
care utilization by and clinical outcomes of: 1) neonates
who were referred to a pediatrician for neonatal admis-
sion, had a birth weight <5th percentile or a severe ad-
verse perinatal outcome, e.g. Apgar score 5 min after
birth <4, as indicated in the Perined database; and 2)
women participating in the survey and being referred to
a gynecologist/secondary care during the perinatal
period, and women having a neonate who has been re-
ferred to a pediatrician, has a birth weight <5th percent-
ile or a severe adverse perinatal outcome. The
standardized case report forms will also be used to col-
lect information on professionals’ adherence to the
multidisciplinary consensus-based IRIS study protocol
for the detection and clinical management of IUGR. By
focusing on this group of neonates and women, we are
able to efficiently collect data on severe adverse perinatal
outcome, maternal perinatal morbidity, healthcare
utilization, and protocol adherence which would not
have been feasible in all 15,000 women.
Statistical analyses
Sample size of the trial
Our sample size calculation was based on our primary
dichotomous outcome, i.e. severe adverse perinatal out-
come. Perined data suggest that the expected rate of se-
vere adverse perinatal outcome in the source population,
i.e. low-risk pregnant women in the Netherlands, is
1.54 %. Neither nationally nor internationally it has been
agreed which degree of reduction in severe adverse peri-
natal outcome can be considered as feasible and clinic-
ally relevant. Therefore, the IRIS study group decided to
aim at a reduction from 1.54 % to 1.0 % in the primary
outcome. With 80 % power and a significance level of p
< 0.05, 13,536 pregnant women should be included. Yet,
due to the clustered design our sample size calculation
also needs to take dependency of data into account.
Pagel et al. (2011) estimated the intracluster correlation
coefficients (ICCs) for a range of offspring perinatal out-
comes using data from five community‐based cluster-
randomized trials in three low‐income countries [47].
Five ICCs ranging from 0.0003 to 0.002 were reported
for neonatal mortality [47]. We expect the ICC in the
IRIS study to be much more similar to 0.0003 than to
0.002 for the following two reasons. First, the ICCs pre-
sented in the paper by Pagel et al. (2011) are based on
prevalence rates of neonatal mortality ranging from
1.5 % to 5.9 % indicating a higher maximum rate than
the rate of severe adverse perinatal outcome expected
for the IRIS study, i.e. 1.54 % [47]. Since ICCs are ex-
pected to be related to low prevalences of the outcome
of interest, we may assume the ICC in the IRIS study to
be even lower than 0.0003. Second, participating midwif-
ery practices will offer both CAU, and later on, routine
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third trimester ultrasound screening. Due to this, the
variation in characteristics and practice management be-
tween the clusters, i.e. midwifery practices, will be re-
duced and, consequently, the size of the ICC will be
lowered. Using the formula to correct for clustering [1
+ (n‐1) * ICC] with n = 250, i.e. average cluster size in
our study, the required sample size for the IRIS study is
14,547 women. Since not all pregnant women may be
recruited exactly at 20–22 weeks of pregnancy, we de-
cided to include a total of 15,000 pregnant women.
Effectiveness analyses
First, we will compare baseline characteristics of women
participating in the intervention and control group using
independent t-tests and chi-square tests. Second, we will
compare baseline characteristics of drop-outs and com-
pleters by using independent t-tests and chi-square tests.
Third, we will perform multiple logistic multilevel re-
gression analysis to test the possible effect of routine
third trimester ultrasound screening on severe adverse
perinatal outcome. This analysis will be adjusted for pos-
sible clustering of observations at the level of midwifery
practices and medical/biological, demographic and life-
style related confounders. In all analyses, we will use an
intention-to-treat approach and set the level of signifi-
cance at p < 0.05.
Economic evaluation
The economic evaluation aims to compare the costs
generated by pregnant women receiving routine third
trimester ultrasound screening versus those receiving
CAU. Both a cost-effectiveness and cost-utility analysis
will be conducted using different perspectives and time
horizons.
Cost‐effectiveness and cost‐utility analyses
First, we will perform a cost‐effectiveness analysis from a
healthcare perspective. The time horizon of this analysis
ranges from 22 weeks of gestation to one week after the
date of birth of the child. In this analysis, pregnancy related
data derived from the Perined database of all 15,000 partici-
pating women will be used. Detailed cost data collected by
research assistants/nurses from medical records of women
participating in the random (n = 900) and non-random
sample (n = 600) will be used to estimate the healthcare
costs for the whole study population (n = 15,000) using
Bayesian techniques in combination with Monte Carlo
simulation. Incremental Cost‐Effectiveness Ratios (ICER)
will be calculated by dividing the difference in healthcare
costs by the difference in effects.
Second, we will perform a cost‐effectiveness analysis
from a societal perspective. The time horizon of this ana-
lysis ranges from 22 weeks of gestation until 6 months
after the estimated date of delivery. Again, pregnancy
related data derived from the Perined database of all
15,000 participating women will be used in this analysis.
Detailed cost data collected by research assistants/nurses
from medical records, and self-report utilization and lost
productivity data of women participating in the random
(n = 900) and non-random (n = 600) sample will be used
to estimate societal costs for the whole study population
(n = 15,000) by applying Bayesian techniques in combin-
ation with Monte Carlo simulation. Furthermore, the
combination of direct costs and indirect costs (based on
maternal reports of absenteeism and presenteeism at (un-
paid) work measured with the iPCQ [29]) will be related
to the composite of severe adverse perinatal outcome to
estimate the ICER.
Finally, a cost‐utility analysis from a societal perspective
will be performed. The time horizon of this analysis ranges
from 22 weeks of gestation until 6 months after the ex-
pected date of delivery. For this analysis, data of the 900
women in the random sample will be used. Quality‐Ad-
justed Life‐Years (QALYs) will be calculated based on the
EQ‐5D‐5 L using the Dutch tariff) [48]. Incremental Cost‐
Utility Ratios (ICURs) will be calculated by relating the dif-
ference in costs between the conditions to the difference in
QALYs. In this analysis, missing cost and effect data will be
imputed using multiple imputation based on the MICE al-
gorithm developed by Van Buuren et al. (1999) [49]. Bias‐
corrected and accelerated bootstrapping with 5000 replica-
tions will be used to estimate 95 % confidence intervals
around cost differences and the uncertainty surrounding
the ICERs and ICUR.
Both the cost‐effectiveness and cost‐utility analyses will
be conducted using an intention‐to‐treat approach. For all
analyses uncertainty surrounding the ICERs and ICUR
will be graphically presented on cost‐effectiveness planes.
Cost‐effectiveness acceptability curves will also be esti-
mated using the net benefit framework [50]. Cost‐effect-
iveness acceptability curves will illustrate the probability
that routine third trimester ultrasound screening for
IUGR is cost‐effective (or not) as compared to CAU for a
range of various ceiling ratios thereby demonstrating deci-
sion uncertainty.
Description of sub-studies
Sub-study A
The first sub-study will concern a Delphi study aiming
to develop a multidisciplinary protocol for the screening
for, detection of, and subsequent management of IUGR
in prenatal care in the Netherlands. Currently, the exist-
ing Dutch guidelines of the KNOV and NVOG for IUGR
detection and/or management are not fully aligned and
differ in scope potentially resulting in inconsistencies in
clinical management between healthcare professionals
[26, 27]. To facilitate multidisciplinary collaboration be-
tween professionals in primary and secondary/tertiary
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care and to develop uniform recommendations for IUGR
screening and management participating panel members
will receive structured online questionnaires in three
rounds to achieve consensus about IUGR items. The
questionnaires will address identified inconsistencies in
the Dutch monodisciplinary KNOV and NVOG guide-
lines and will also be based on the evidence-based Brit-
ish guideline of the Royal College of Obstetricians and
Gynaecologists (RCOG) [51]. This latter guideline ad-
dresses aspects of both screening for IUGR in the gen-
eral population and additional examinations and
management of IUGR. Panel members will be Dutch
midwives, obstetricians, and sonographers, and national
experts/researchers in IUGR and/or fetal biometry and
monitoring. The multidisciplinary recommendations for
IUGR screening and management resulting from this
sub-study will be incorporated in the screening and
management protocol of the IRIS study.
Sub-study B
In sub-study B we will investigate which ethical dilemmas
concerning positive, unexpected, or unclear third trimes-
ter ultrasound findings and incorrect indication of IUGR
the involved professionals and pregnant women experi-
ence and which recommendations they give for dealing
with these ethical dilemmas in the future. For this purpose
different qualitative methods will be used in an iterative
way of working. First, an explorative literature study will
be conducted to examine ethical dilemmas of pregnant
women and professionals regarding decision-making,
ultrasound screening procedures, and communication of
ultrasound findings. Second, a purposively selected sub-
sample of pregnant women (n = 32) participating in the
intervention group will keep a textual, semi-structured
diary for 9 months (from the beginning of late pregnancy
until 6 months postpartum). In the diary study data on
pregnant women’s experiences of the informed consent
procedure, ultrasound screening, and ethical dilemmas
(e.g., dealing with unexpected findings) will be collected.
Third, among a subgroup of pregnant women (n = 10) in-
dividual semi-structured interviews will be held at
6 months postpartum to further explore thoughts and
feelings about the third trimester ultrasound screening
and related ethical dilemmas. Finally, two focus group in-
terviews (n ~ 10) will be performed: one consisting of indi-
vidually interviewed pregnant women and caregivers and
the other group comprising multidisciplinary prenatal care
professionals. Purposes of these focus group interviews
will be: (a) deepen the understanding of the ethical di-
lemmas of pregnant women and caregivers, (b) validation
of ethical dilemmas, and (c) establishing recommenda-
tions for future practice. Participants of sub-study B will
be asked for written informed consent.
Discussion
Sensitive measures to detect IUGR during late preg-
nancy and subsequent adequate clinical management of
IUGR are important to decrease perinatal mortality and
morbidity. This large-scale nationwide stepped wedge
cluster-randomized trial will provide evidence whether
or not routine third trimester ultrasound screening in
combination with protocolized management is clinically
effective and cost-effective as compared to CAU in redu-
cing severe adverse perinatal outcome.
The current study has several strengths: it will fill cru-
cial knowledge gaps in the domain of screening for and
management of IUGR and is, therefore, expected to have
important clinical implications. First, a major spin-off of
the IRIS study is the development of a consensus-based
multidisciplinary protocol for the detection and manage-
ment of IUGR. This protocol can be used as starting
point for the development of a multidisciplinary guide-
line for prenatal care of IUGR in the Netherlands. Sec-
ond, as recommended in the recent Cochrane review by
Bricker et al. (2015), the current study extends previous
work by investigating the impact of routine third trimes-
ter ultrasound screening on maternal prenatal and post-
natal psychological functioning and on long-term
offspring neurodevelopmental outcome [14]. Third, we
will identify pregnant women’s and professionals’ ethical
dilemmas related to positive, unexpected and unclear
findings during ultrasound screening. Based on these re-
sults recommendations for future practice can be formu-
lated. Fourth, a methodological strength of our trial is its
large sample size. In comparison to most previous stud-
ies [14], the current trial is adequately powered to exam-
ine whether third trimester ultrasound screening can
reduce severe adverse perinatal outcome. Finally and im-
portantly, our trial examines the cost-effectiveness and
cost-utility of routine third trimester ultrasound screen-
ing among low-risk pregnancies as compared to CAU.
The results of the effectiveness and cost-effectiveness
study will assist healthcare providers and policymakers
in making an educated choice about whether or not
introducing routine third trimester ultrasound screening
in the Netherlands.
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